SEBI Reg. Investment Advisor

Download App

Help Center Pricing

Recent:

Top Pharma Companies in India by Market Cap

BSE Sensex 77328.19
516.33 (-0.66%)

Filter

Top Pharma Companies in India as on May-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
91	Eris Lifesciences Ltd.	Q V PT	19,212 Small Cap	1,386.75 (0.22%)	44.4	5.29	21.92	3.58	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
92	Aurobindo Pharma Ltd.	Q V+ PT	86,452 Mid Cap	1,488.50 (0.67%)	40.3	3.9	-3.95	-0.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
93	Ipca Laboratories Ltd.	Q V+ PT	39,369 Mid Cap	1,551.75 (-0.39%)	49.09	5.13	8.87	4.68	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
94	Wockhardt Ltd.	Q V+ PT	26,111 Small Cap	1,606.90 (-1.82%)	124.86	5.38	1.15	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
95	Emcure Pharmaceuticals Ltd.	Q V PT	31,123 Small Cap	1,641.60 (-1.28%)	43.01	8.5	13.02	9.98	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
96	Hester Biosciences Ltd.	Q V+ PT	1,403 Small Cap	1,649.65 (0.70%)	39.42	3.89	11.08	0.75	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
97	Poly Medicure Ltd.	Q V PT	16,736 Small Cap	1,651.20 (-1.69%)	49.77	5.74	19.91	26.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
98	Dr. Lal Pathlabs Ltd.	Q V PT	27,689 Small Cap	1,651.70 (5.43%)	51.68	10.62	13.05	17.98	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
99	CORONA Remedies Ltd.	Q V+ PT	10,472 Small Cap	1,712.15 (-1.50%)	71.33	15.18	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
100	Kwality Pharmaceuticals Ltd.	Q V+ PT	1,817 Small Cap	1,751.25 (2.10%)	31.47	5.8	21.70	37.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
101	Narayana Hrudayalaya Ltd.	Q V+ PT	37,189 Mid Cap	1,819.75 (-2.27%)	48.85	9.08	11.88	45.85	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
102	Onesource Specialty Pharma Ltd.	Q V PT	21,048 Small Cap	1,835.95 (1.07%)	119.27	3.51	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
103	Sun Pharmaceutical Industries Ltd.	Q V+ PT	4,43,229 Large Cap	1,847.30 (0.70%)	40.32	5.42	9.87	23.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
104	Caplin Point Laboratories Ltd.	Q V PT	14,118 Small Cap	1,857.35 (-0.47%)	23.11	4.27	17.55	21.52	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
105	Gland Pharma Ltd.	Q V PT	31,377 Small Cap	1,904.45 (1.78%)	26.37	2.98	9.35	7.37	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
106	JB Chemicals & Pharmaceuticals Ltd.	Q V+ PT	34,551 Small Cap	2,151.90 (0.49%)	47.27	8.81	17.81	19.45	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
107	Glenmark Pharmaceuticals Ltd.	Q V+ PT	66,722 Mid Cap	2,364.35 (-0.28%)	62.82	6.7	4.60	14.41	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
108	Lupin Ltd.	Q V PT	1,08,721 Mid Cap	2,377.90 (-3.33%)	21.09	5.4	8.11	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
109	Mankind Pharma Ltd.	Q V PT	1,00,200 Mid Cap	2,427.15 (2.18%)	57.56	6.14	14.65	12.79	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
110	RPG Life Sciences Ltd.	Q V+ PT	4,067 Small Cap	2,458.95 (-0.89%)	35.63	6.78	11.71	30.85	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
111	Glaxosmithkline Pharmaceuticals Ltd.	Q V+ PT	42,092 Mid Cap	2,484.70 (0.23%)	41.13	20.96	3.06	33.10	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
112	Acutaas Chemicals Ltd.	Q V+ PT	22,377 Small Cap	2,733.15 (0.42%)	60.85	13.36	32.80	16.82	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
113	Ajanta Pharma Ltd.	Q V PT	37,883 Small Cap	3,032.20 (-1.56%)	36.44	8.5	12.43	17.07	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
114	Sanofi India Ltd.	Q V PT	7,664 Small Cap	3,327.85 (-1.90%)	25.22	10.02	-8.74	-7.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
115	Torrent Pharmaceuticals Ltd.	Q V+ PT	1,48,251 Large Cap	4,380.35 (0.49%)	64.93	16.24	7.72	15.29	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
116	Sanofi Consumer Healthcare India Ltd.	Q V+ PT	10,993 Small Cap	4,773 (0.28%)	42.5	24.26	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
117	Pfizer Ltd.	Q V PT	22,009 Small Cap	4,811.05 (1.29%)	25.46	5.45	1.18	5.79	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
118	Dr Agarwals Eye Hospital Ltd.	Q V PT	2,465 Small Cap	5,101.30 (0.74%)	35.04	7.37	17.68	31.54	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
119	Procter & Gamble Health Ltd.	Q V PT	8,883 Small Cap	5,351.35 (0.70%)	30.06	12.65	4.31	11.97	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
120	Alkem Laboratories Ltd.	Q V+ PT	66,679 Mid Cap	5,576.80 (-0.25%)	30.47	4.68	5.71	10.33	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
Metropolis Health.	550.30	8.83%
Shree Ganesh Remed.	530.60	8.65%
KMC Speciality Hosp	95.47	6.85%
Guj. Kidney & Super	139.85	6.84%
Nectar Lifesciences	14.39	5.89%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
Indoco Remedies	228.20	-9.17%
Windlas Biotech	820.55	-4.24%
Panacea Biotec	388.15	-4.16%
Fermenta Biotech	288.70	-4.07%
Lupin	2,377.90	-3.33%

News about Top Pharma Companies in India

May, 2026

USFDA completes inspection at Alkem Laboratories’ CRO facility in Taloja

At the end of the inspection, no form 483 was issued

May, 2026

Emcure Pharmaceuticals informs about ESG rating

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Part A Para A of Schedule III and SEBI Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, Emcure Pharmaceuticals has informed that NSE Sustainability Ratings & Analytics, a SEBI registered Environmental, Social, and Governance (ESG) Rating Provider, has voluntarily and independently assigned ESG rating of 21 to the Company, for the Financial Year 2024-25, based on information available in public domain. This disclosure is being made based on the information received by the Company vide email dated May 07, 2026, about such rating.

The above information is a part of company’s filings submitted to BSE.

May, 2026

Aurobindo Pharma zooms after getting EIR for Telangana unit

The USFDA has classified the said facility as Voluntary Action Indicated

May, 2026

Aurobindo Pharma gets EIR for Telangana unit

The USFDA has classified the said facility as Voluntary Action Indicated

May, 2026

Aurobindo Pharma informs about updates

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Aurobindo Pharma has informed that the United States Food and Drug Administration (US FDA) inspected Aurobindo Pharma’s Unit-VII, an oral solid dosage manufacturing unit, situated at Special Economic Zone (Pharma), TSIIC, Green Industrial Park, Polepally Village, Jedcherla Mandal, Mahaboobnagar District, 509302, Telangana from January 28 to February 10, 2026. At the end of the inspection, a ‘Form 483’ was issued with a total of 9 observations. The Unit has now received Establishment Inspection Report (EIR) classifying the facility as ‘Voluntary Action Indicated’ (‘VAI’). FDA has concluded that this inspection is now closed.

The above information is a part of company’s filings submitted to BSE.

May, 2026

Ajanta Pharma - Quaterly Results

The Revenue for the quarter ended March 2026 of Rs. 12105.30 millions grew by 19.39 % from Rs. 10139.40 millions.Net profit showed a marginal rise at Rs. 1972.80 millions for the quarter ended March 2026, as compared to corresponding quarter of last year.Operating profit surged to 3010.30 millions from the corresponding previous quarter of 2675.80 millions.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202603	202503	% Var	202603	202503	% Var	202603	202503	% Var
Sales	12105.30	10139.40	19.39	48459.20	43220.40	12.12	48459.20	43220.40	12.12
Other Income	629.80	179.30	251.25	2044.00	1198.70	70.52	2044.00	1198.70	70.52
PBIDT	3010.30	2675.80	12.50	14023.90	13245.90	5.87	14023.90	13245.90	5.87
Interest	-7.40	6.70	-210.45	25.90	46.00	-43.70	25.90	46.00	-43.70
PBDT	3017.70	2669.10	13.06	13998.00	13199.90	6.05	13998.00	13199.90	6.05
Depreciation	441.60	387.60	13.93	1687.70	1399.30	20.61	1687.70	1399.30	20.61
PBT	2576.10	2281.50	12.91	12310.30	11800.60	4.32	12310.30	11800.60	4.32
TAX	603.30	347.20	73.76	2842.10	2631.70	7.99	2842.10	2631.70	7.99
Deferred Tax	-70.00	-43.80	59.82	76.00	51.40	47.86	76.00	51.40	47.86
PAT	1972.80	1934.30	1.99	9468.20	9168.90	3.26	9468.20	9168.90	3.26
Equity	250.70	250.70	0.00	250.70	250.70	0.00	250.70	250.70	0.00
PBIDTM(%)	24.87	26.39	-5.77	28.94	30.65	-5.57	28.94	30.65	-5.57

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Nectar Lifesciences Ltd.	280 Crore
2	Syncom Formulations (India) Ltd.	1,383 Crore
3	Sigachi Industries Ltd.	841 Crore
4	Fischer Medical Ventures Ltd.	2,451 Crore
5	Morepen Laboratories Ltd.	2,504 Crore
6	Anuh Pharma Ltd.	843 Crore
7	KMC Speciality Hospitals (India) Ltd.	1,557 Crore
8	IOL Chemicals And Pharmaceuticals Ltd.	2,847 Crore
9	Themis Medicare Ltd.	902 Crore
10	Gujarat Kidney And Super Speciality Ltd.	1,103 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	26,661	56,654	37.17	12.91	26.02	35.71
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,380	1,48,251	65.25	16.32	36.87	26.68
Ajanta Pharma Ltd. (S)	Very Good	3,032	37,883	35.87	8.37	24.25	24.45
Lupin Ltd. (M)	Somewhat Good	2,378	1,08,721	20.39	4.84	11.79	20.83
Zydus Lifesciences Ltd. (M)	Very Good	939	94,475	19.13	3.60	11.91	20.74

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,229	66,373	110
Glenmark Pharmaceuticals Ltd. (M)	Very Good	2,364	66,722	67.00
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,152	34,551	40.02
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,380	1,48,251	37.62
Gland Pharma Ltd. (S)	Very Good	1,904	31,377	34.73
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,152	34,551	47.50	8.85	30.00	17.81
Mankind Pharma Ltd. (M)	Very Good	2,427	1,00,200	58.82	6.28	35.25	14.65
Laurus Labs Ltd. (M)	Very Good	1,229	66,373	74.68	12.52	37.46	14.42
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,293	1,07,942	19.38	2.90	11.65	13.26
Ajanta Pharma Ltd. (S)	Very Good	3,032	37,883	35.87	8.37	24.25	12.43

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Zydus Lifesciences Ltd. (M)	Very Good	939	94,475	19.13	3.60	11.91	30.57
Cipla Ltd. (L)	Very Good	1,348	1,08,865	23.95	3.24	14.44	30.14
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,847	4,43,229	40.61	5.46	22.21	23.50
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,293	1,07,942	19.38	2.90	11.65	22.29
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,152	34,551	47.50	8.85	30.00	19.45

You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

USFDA completes inspection at Alkem Laboratories’ CRO facility in Taloja

Emcure Pharmaceuticals informs about ESG rating

Aurobindo Pharma zooms after getting EIR for Telangana unit

Aurobindo Pharma gets EIR for Telangana unit

Aurobindo Pharma informs about updates

Ajanta Pharma - Quaterly Results

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.